April 3, 2025 10:52 AM EDT

Aldeyra gets another CRL for its dry eye disease drug that AbbVie has the option to co-develop

Kyle LaHucik

Senior Reporter

The FDA once again rejected Aldeyra’s potential dry eye disease treatment, known as reproxalap, as the agency requested more trial data after the resubmitted drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aldeyra gets another CRL for its dry eye disease drug that AbbVie has the option to co-develop

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA will consolidate to five 'shared services offices,' according to memo to Hill staffers

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Trump has touted Right to Try as a lifesaver. Several government staff supporting it were just let go

Trump’s broad tariffs exempt pharma — but for how long?

Chaotic tariff rollout leaves as many questions as answers for drugmakers

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Aldeyra gets an­oth­er CRL for its dry eye dis­ease drug that Ab­b­Vie has the op­tion to co-de­vel­op

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

FDA will con­sol­i­date to five 'shared ser­vices of­fices,' ac­cord­ing to memo to Hill staffers

Roche plans Phase 3 for its lat­est Alzheimer’s drug at­tempt af­ter un­veil­ing more ear­ly da­ta

Trump has tout­ed Right to Try as a life­saver. Sev­er­al gov­ern­ment staff sup­port­ing it were just let go

Trump’s broad tar­iffs ex­empt phar­ma — but for how long?

Chaot­ic tar­iff roll­out leaves as many ques­tions as an­swers for drug­mak­ers

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Aldeyra gets another CRL for its dry eye disease drug that AbbVie has the option to co-develop

FDA will consolidate to five 'shared services offices,' according to memo to Hill staffers

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Trump has touted Right to Try as a lifesaver. Several government staff supporting it were just let go

Trump’s broad tariffs exempt pharma — but for how long?

Chaotic tariff rollout leaves as many questions as answers for drugmakers

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO